ETIMS ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01414634 (ClinicalTrials.gov)	February 2010	8/8/2011	Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells	Establish Tolerance in Multiple Sclerosis With Peptide-coupled, Peripheral Blood Mononuclear Cells - A MRI-controlled, Single Center, Phase I Trial in Relapsing-remitting MS Patients	Multiple Sclerosis, Relapsing-Remitting	Biological: ETIMS	Universitätsklinikum Hamburg-Eppendorf	NULL	Completed	18 Years	55 Years	All	9	Phase 1/Phase 2	NULL
2	EUCTR2008-004408-29-DE (EUCTR)	27/11/2009	31/07/2008	ESTABLISH TOLERANCE IN MS WITH PEPTIDE-PULSED, PERIPHERAL BLOOD MONONUCLEAR CELLS - A MRI-CONTROLLED, SINGLE CENTER, BASELINE-TO-TREATMENT CROSS-OVER, PHASE I/IIA TRIAL IN RELAPSING-REMITTING MS PATIENTS - ETIMS - - ETIMS	ESTABLISH TOLERANCE IN MS WITH PEPTIDE-PULSED, PERIPHERAL BLOOD MONONUCLEAR CELLS - A MRI-CONTROLLED, SINGLE CENTER, BASELINE-TO-TREATMENT CROSS-OVER, PHASE I/IIA TRIAL IN RELAPSING-REMITTING MS PATIENTS - ETIMS - - ETIMS	relapsing-remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis	Product Name: ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients) Product Code: ETIMS	University Medical Center Hamburg-Eppendorf	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 1/2	Germany